{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:02:12Z","timestamp":1770822132037,"version":"3.50.1"},"reference-count":20,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although imatinib is clearly the treatment of choice for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia (CEL), little is known about optimal dosing, duration of treatment, and the possibility of cure in this disorder. To address these questions, 5 patients with FIP1L1\/PDGFRA-positive CEL with documented clinical, hematologic, and molecular remission on imatinib (400 mg daily) and without evidence of cardiac involvement were enrolled in a dose de-escalation trial. The imatinib dose was tapered slowly with close follow-up for evidence of clinical, hematologic, and molecular relapse. Two patients with endomyocardial fibrosis were maintained on imatinib 300 to 400 mg daily and served as controls. All 5 patients who underwent dose de-escalation, but neither of the control patients, experienced molecular relapse (P &lt; .05). None developed recurrent symptoms, and eosinophil counts, serum B12, and tryptase levels remained suppressed. Reinitiation of therapy at the prior effective dose led to molecular remission in all 5 patients, although 2 patients subsequently required increased dosing to maintain remission. These data are consistent with suppression rather than elimination of the clonal population in FIP1L1\/PDGFRA-positive CEL and suggest that molecular monitoring may be the most useful method in determining optimal dosing without the risk of disease exacerbation. This trial was registered at http:\/\/www.clinicaltrials.gov as no. NCT00044304.<\/jats:p>","DOI":"10.1182\/blood-2007-07-100164","type":"journal-article","created":{"date-parts":[[2007,8,20]],"date-time":"2007-08-20T20:59:50Z","timestamp":1187643590000},"page":"3552-3556","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing"],"prefix":"10.1182","volume":"110","author":[{"given":"Amy D.","family":"Klion","sequence":"first","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases (NIAID),"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Robyn","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung and Blood Institute (NHLBI);"},{"name":"Laboratory of Allergic Diseases, NIAID;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Maric","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Warren Grant Magnusson Clinical Center; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Warren Grant Magnusson Clinical Center; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Schmid","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases (NIAID),"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Lemery","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung and Blood Institute (NHLBI);"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Noel","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Warren Grant Magnusson Clinical Center; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa A.","family":"Law","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases (NIAID),"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Hartsell","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases (NIAID),"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Talar-Williams","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases (NIAID),"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Fay","sequence":"additional","affiliation":[{"name":"Biostatistics Research Branch, NIAID, National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia E.","family":"Dunbar","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung and Blood Institute (NHLBI);"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B.","family":"Nutman","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases (NIAID),"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111712372108000_B1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111712372108000_B2","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"2019111712372108000_B3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"2019111712372108000_B4","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"key":"2019111712372108000_B5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatiinb mesylate therapy.","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"2019111712372108000_B6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable completye cytogenetic response to imatinib.","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia"},{"key":"2019111712372108000_B7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A novel tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111712372108000_B8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.","volume":"103","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"2019111712372108000_B9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1\/PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"2019111712372108000_B10","first-page":"1117","article-title":"Imatinib mesyalte therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.","volume":"88","author":"Cervantes","year":"2003","journal-title":"Haematologica"},{"key":"2019111712372108000_B11","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111712372108000_B12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2005.05863.x","article-title":"Multilineage involvement of the fusion gene in patients with FIP1L1\/PDGFRA-positive hypereosinophilic syndrome.","volume":"132","author":"Robyn","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111712372108000_B13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111712372108000_B14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/asheducation-2001.1.87","article-title":"Chronic myelogenous leukemia.","volume":"2001","author":"Druker","journal-title":"Hematology"},{"key":"2019111712372108000_B15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete remission for more than two years.","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"2019111712372108000_B16","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving molecular response.","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"2019111712372108000_B17","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"key":"2019111712372108000_B18","first-page":"9790981","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"key":"2019111712372108000_B19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jjco\/hyl088","article-title":"Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.","volume":"36","author":"Lee","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"2019111712372108000_B20","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/10\/3552\/1290397\/zh802207003552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/10\/3552\/1290397\/zh802207003552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T12:37:32Z","timestamp":1573994252000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/10\/3552\/23356\/Relapse-following-discontinuation-of-imatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,15]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-07-100164","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,15]]}}}